SCHEMBL3586613

SCHEMBL3586613

CCOC(=O)c1cc(-c2cc(O)c(O)c([N+](=O)[O-])c2)n(C)c1-c1cccc(F)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.44
MAPT P10636 6/20 0.38
HPGD P15428 4/20 0.37
NPSR1 Q6W5P4 2/20 0.37
GAA P10253 1/20 0.37
HTT P42858 1/20 0.37
LMNA P02545 3/20 0.36
CCR6 P51684 2/20 0.36
KMT2A Q03164 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
GMNN O75496 1/20 0.35
TTR P02766 1/20 0.35
TP53 P04637 1/20 0.35
CYP3A4 P08684 1/20 0.35
THRB P10828 1/20 0.35
CYP2C9 P11712 1/20 0.35
TSHR P16473 1/20 0.35
NFKB1 P19838 1/20 0.35
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1447238 0.84 MAPT (0.38) ALDH1A1MAPTHPGDNPSR1GAA
SCHEMBL3587266 0.78 ALDH1A1 (0.38) ALDH1A1MAPTHPGDNPSR1LMNA
SCHEMBL3584510 0.78 ALDH1A1 (0.36) ALDH1A1MAPTHPGDLMNAKMT2A
SCHEMBL3589502 0.78 MAPT (0.40) ALDH1A1MAPTHPGDNPSR1LMNA
SCHEMBL3581807 0.77 CRHBP (0.39) ALDH1A1MAPTHPGDLMNAKMT2A
SCHEMBL1446919 0.77 MAPT (0.36) ALDH1A1MAPTHPGDNPSR1GAA
SCHEMBL3581343 0.77 MAPT (0.39) ALDH1A1MAPTHPGDNPSR1GAA
SCHEMBL1446969 0.76 ALDH1A1 (0.36) ALDH1A1MAPTHPGDNPSR1LMNA
SCHEMBL1446983 0.75 COMT (0.40) ALDH1A1MAPTHPGDNPSR1LMNA
SCHEMBL3583587 0.71 ALDH1A1 (0.39) ALDH1A1MAPTHPGDNPSR1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9446012-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-09-20 US disclosed
US-20140024682-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & CA, S.A. (PT) 2014-01-23 US disclosed
US-8536203-B2 Pharmaceutical compounds BIAL-PORTELA & CA, S.A. (PT) 2013-09-17 US disclosed
EP-2617713-A1 New Pharmaceutical Compounds BIAL - Portela & Ca., S.A. (PT) 2013-07-24 EP disclosed
US-20100168113-A1 Pharmaceutical Compounds BIAL-PORTELA & CA., S.A. (PT) 2010-07-01 US disclosed
EP-2027091-A1 NEW PHARMACEUTICAL COMPOUNDS BIAL - Portela & Ca., S.A. (PT) 2009-02-25 EP disclosed
WO-2007117165-A1 NEW PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & CA, S.A. (PT) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168113-A1 Pharmaceutical Compounds PMP22, CNR2, OPRL1 ALDH1A1 1070/4885MAPT 310/4885HPGD 307/4885
US-20140024682-A1 PHARMACEUTICAL COMPOUNDS PMP22, CNR2, OPRL1 ALDH1A1 1070/4885MAPT 310/4885HPGD 307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.